Biofrontera

Biofrontera Days Payable Outstanding

The Days Payable Outstanding (DPO) of Biofrontera (B8FK.DE) as of Nov 21, 2026 is 233.73. In the previous year, Days Payable Outstanding (DPO) was 374.88 — a change of -37.65% (lower).

Days Payable Outstanding

233.73

YoY

-37.65%

Last updated:

Days Payable Outstanding (DPO) of Biofrontera is 2025 233.73 . Days Payable Outstanding (DPO) of Biofrontera was 2024 374.88 . It decreases by -37.65% lower compared to the previous year.

The Biofrontera Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2018
148.10 EUR
Jan 1, 2019
314.16 EUR
Jan 1, 2020
167.53 EUR
Jan 1, 2021
255.12 EUR
Jan 1, 2022
152.26 EUR
Jan 1, 2023
137.62 EUR
Jan 1, 2024
374.88 EUR
Jan 1, 2025
233.73 EUR
The Biofrontera Days Payable Outstanding history
YEARDays Payable OutstandingYoY
233.73-37.65%
374.88+172.41%
137.62-9.62%
152.26-40.32%
255.12+52.28%
167.53-46.67%
314.16+112.13%
148.10-35.81%
230.71-50.11%
462.40+50.01%
308.25-2.52%
316.22—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biofrontera Stock analysis

What does Biofrontera do? Biofrontera AG generates revenue by developing, selling, and distributing dermatological drugs and medical cosmetics for skin care, protection, and treatment. The company markets its portfolio which includes Ameluz for the photodynamic therapy of actinic keratoses, the PDT lamp BF-RhodoLED used in conjunction with Ameluz treatment, and Belixos, a herbal dermatological cream for conditions such as insect bites, burns, neurodermatitis, and psoriasis. These products address the needs of patients and healthcare providers seeking treatments for skin diseases and regenerative care of damaged skin. The firm also engages in the clinical development of drug candidates to expand its future revenue streams. This includes BF-derm1, a tablet containing an inhibitor that blocks histamine synthesis to prevent allergic reactions, and BF1, a selective serotonin receptor agent aimed at preventing migraines. Through its five wholly owned subsidiaries, notably B, Biofrontera AG supports these development and distribution activities from its headquarters in Leverkusen, Nordrhein-Westfalen. Biofrontera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biofrontera stock

Days Payable Outstanding (DPO) of Biofrontera is 233.73 in 2025.

Days Payable Outstanding (DPO) of Biofrontera changed from 374.88 to 233.73, representing a -37.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) Biofrontera since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s Biofrontera with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Biofrontera

All Key Metrics — Biofrontera